Hims & Hers Health (HIMS) News Today

Hims & Hers Health, Inc. (NYSE: HIMS) shares decreased as investors weighed renewed legal and regulatory concerns against potential growth from peptide treatments and international expansion.

• Positive Sentiment: Peptide-compounding policy could reopen a major growth opportunity. Reports that the Trump administration and the Department of Health and Human Services are reviewing a plan related to compounded peptides raised hopes that Hims & Hers could regain access to a potentially significant weight-management market. Hims and Hers Health rises as HHS moves ahead with plan for compounding peptides
• Positive Sentiment: Australian expansion adds a longer-term revenue catalyst. Hims & Hers launched its Hers women’s-health platform in Australia following its $1.15 billion acquisition of Eucalyptus. The expansion broadens the company’s international footprint and offerings in weight management, hormonal health and hair regrowth. Hims and Hers launches Hers in Australia following Eucalyptus acquisition
• Neutral Sentiment: Insider selling provided a modest negative signal but was pre-arranged. Insider Soleil Boughton sold 3,461 shares for approximately $100,577 under a Rule 10b5-1 trading plan, reducing her holdings by about 1.15%. The scheduled nature and relatively small size of the transaction limit its significance. Hims and Hers Health insider stock sale
• Negative Sentiment: Securities litigation intensified investor concerns. Several law firms publicized a federal securities class action against Hims & Hers and certain executives, citing allegations connected to the FTC’s complaint over alleged business misconduct. Investors who acquired shares between August 4, 2025, and July 29, 2026, have until November 2, 2026, to seek lead-plaintiff status. The legal action could increase costs, reputational pressure and potential liabilities; the numerous announcements appear to concern the same lawsuit rather than separate cases. Hims and Hers Health securities class action alert